Results 161 to 170 of about 302,518 (309)

Chronic hepatitis B: Is it time for expanded antiviral treatment? [PDF]

World J Virol
Manrai M, Jha AA, Pachisia AV, Dawra S.
europepmc   +1 more source

Chemical and Biological Properties of Hymenaea courbaril L.: A Review

Chemistry &Biodiversity, EarlyView.
PRISMA‐style flowchart showing the screening process of studies identified and selected in the review has been added to the attachments. ABSTRACT Hymenaea courbaril L., commonly known as jatobá, is a plant traditionally used by native populations for medicinal purposes, in addition to providing edible fruits and durable wood for construction.
Cicera Alane Coelho Gonçalves, Geane Gabriele de Oliveira Souza, Ana Maria Fernandes Duarte, Joice Barbosa do Nascimento, Fázia Fernandes Galvão Rodrigues, José Galberto Martins da Costa, Fabíola Fernandes Galvão Rodrigues   +6 more
wiley   +1 more source

Expression and significance of INTS10 and IRF3 in chronic hepatitis B patients. [PDF]

Front Microbiol
Ye A, Chen X, Qiu D, Wu W.
europepmc   +1 more source

PP-006 Adefovir resistance detection in chronic hepatitis B patients with primary non-response to adefovir treatment

, 2008
Shangwen Yang, Ran Xue, Q. Wang, Hao Xing, Jian‐You Guo, Wenhui Xie, Jiawei Yan, Jun Cheng   +7 more
openalex   +1 more source

Chronic Type B Hepatitis

Gastroenterology, 1983
openaire   +2 more sources

Lipid Profile Differences in HIV‐Infected Populations With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA study flow diagram. ABSTRACT Introduction Advances in HIV management have transformed HIV into a chronic condition, resulting in improved prognosis and increased survival among people living with HIV (PLWH). Traditional risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD)—including dyslipidemia—are prevalent in PLWH.
Yovita Hartantri, Sherly Lawrensia, Steven Yulius Usman, Nenny Agustanti, Rudi Wisaksana, Nanny Natalia Mulyani Soetedjo, Bachti Alisjahbana   +6 more
wiley   +1 more source

Chronic hepatitis B in 2025: diagnosis, treatment and future directions. [PDF]

Clin Med (Lond)
Watson AG, Mulay AS, Gill US.
europepmc   +1 more source

PGI10 MODELLING THE IMPACT OF TREATMENT WITH ENTECAVIR ON HEALTH CARE COSTS OF CHRONIC HEPATITIS B IN FRANCE

, 2010
JJ Zambrowski, Vlad Ratziu, Marc Bourlière, S. Pol, JP Zarski, Ashley Woolmore, B. Bregman, Sarah Sahraoui, JP Bronowicki   +8 more
openalex   +1 more source

Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis [PDF]

, 1989
Kenneth K. Wang, Albert J. Czaja, Sandra J. Beaver, Vay Liang W. Go   +3 more
openalex   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source